BioRestorative Therapies (BRTX) Research & Development (2011 - 2025)
BioRestorative Therapies' (BRTX) quarterly Research & Development came in at $2.6 million in Q4 2025, up 54.35% YoY from $1.7 million in Q4 2024, and up 1.25% on a QoQ basis from $2.6 million in Q3 2025.
BioRestorative Therapies (BRTX) Research & Development (2011 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 15 years of Research & Development data on file, last reported at $2.6 million in Q4 2025.
- Quarterly Research & Development rose 54.35% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.2 million (up 61.66% YoY) and the FY2025 annual result came in at $10.1 million, up 50.51% from the prior year.
- Research & Development advanced to $2.6 million in Q4 2025, from $2.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $2.6 million in Q4 2025 to a low of $160898.0 in Q2 2021.
- A 5-year average of $1.2 million and a median of $1.1 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2021 — Research & Development sank 38.48% — and 2022, when it jumped 568.26%.
- Tracing BRTX's Research & Development over 5 years: stood at $165496.0 in 2021, then surged by 307.03% to $673621.0 in 2022, then jumped by 61.83% to $1.1 million in 2023, then surged by 56.14% to $1.7 million in 2024, then surged by 54.35% to $2.6 million in 2025.
- The last three Research & Development figures came in at $2.6 million (Q4 2025), $2.6 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | 2.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.63 Mn |
| Sep 30, 2025 | 2.59 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Sep 30, 2024 | 1.45 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.06 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Sep 30, 2023 | 809,824.00 |
| Jun 30, 2023 | 902,891.00 |
| Mar 31, 2023 | 1.23 Mn |
| Dec 31, 2022 | 673,621.00 |
| Sep 30, 2022 | 989,170.00 |
| Jun 30, 2022 | 1.08 Mn |
| Mar 31, 2022 | 775,337.00 |
| Dec 31, 2021 | 165,496.00 |
| Sep 30, 2021 | 256,000.00 |
| Jun 30, 2021 | 160,898.00 |
| Mar 31, 2021 | 165,254.00 |